News

14 rapid reports from CROI 2017, plus journal reviews and sexual health in the UK – including drop in HIV diagnoses, PrEP news, and HPV vaccines…

Some ARVs have shown superior or non-inferior efficacy at reduced doses compared to existing recommended ones. These drugs offer improved durability and tolerability, higher bioavailability, lower pill burden, and the potential for fewer side effects. The ARVs are: dolutegravir (DTG), tenofovir alafenamide …

14 rapid reports from Seattle… new drugs, dolutegravir monotherapy studies stopped, paediatric formulations, PrEP failure case, good news from brain scans… more to follow…

Post-US election issue: reports from Glasgow Congress and Research for Preventions meetings, global treatment, EACS guidelines, UK PrEP updates and more…

Using generic PrEP bought online – new guide for how to use PrEP safely, including options for dosing…

Introduction This year the biennial Glasgow conference was held from 23-26 October 2016. The meeting has a single-track programme making it easy to attend and follow the whole programme, often highlight important European research before it is presented at CROI, …

First reports from this prevention conference being held in Chicago.

PrEP safety, side effects of integrase inhibitors, HIV and children and global access to dolutegravir – reports from four meetings + other news including reduced dose maintenance studies…

This is a small selection of work that was included in a major art exhibition about HIV – either from artists who were/are HIV positive or from other artists responding to the AIDS crisis. The exhibition included about 300 individual …

News from Durban on HIV prevention including TasP and PrEP, paediatrics, TB and cure research – plus news about PrEP in the UK…

Reports from AIDS 2016 include PrEP and new drugs plus news from the pre-conference paediatric and TB workshops…

Simon Collins, HIV i-Base On 29 July 2016, the PROUD study website announced that the study will close without being able to continue to provide participants with oral PrEP. [1] The press release blames NHS England for cancelling the previous …

Simon Collins, VIH i-Base Los resultados del estudio PARTNER publicados en coincidencia con la conferencia AIDS 2016, que se inaugura en Durban (Sudáfrica) la próxima semana, revelan el impacto del tratamiento antirretroviral en la drástica reducción de la transmisión del …

NOTE: For later pipeline reports produced as the i-Base Fit For Purpose publications please see: https://i-base.info/hiv-pipeline-reports-2010-2019 From 2010 – 2016,  i-Base collaborated with Treatment Action Group (TAG) to produce an annual review of latest research. Since 2017, i-Base produce separate …

El siguiente cuestionario está relacionado con el estudio PARTNER que fue publicado en la edición del 12 de julio de 2016 de Journal of the American Medical Association (JAMA), cuya versión completa está disponible de forma gratuita. A continuación se …

Full paper published in JAMA as open access article.

Annual overview of HIV and TB pipeline research: paediatrics and adults

The following letter was sent to Public Health England (PHE) in response to being asked to join a community advisory board for proposed further PrEP research. There are important questions about PrEP but this proposed study is looking at none …

One of the most significant and healthy changes over the last year has been the new energy and activism over HIV prevention work – and for the UK this is particularly notable.  Much of this has been focused on PrEP …

NHS decision to block PrEP, reports from BHIVA, EASL, CROI and HIV and Women conferences, use of HPV vaccine – and remembering i-Base founder Paul Blanchard…